Fig. 2From: Response after treatment with pembrolizumab in a patient with myelophthisis due to melanoma: the role of checkpoint inhibition in the boneChange in patient blood counts over course of treatment with Pembrolizumab. Panel a indicates changes in patient’s white blood cell count (K/mcL) over the period of August 2015 through April 2016. Panel b indicates changes in the patient’s hemoglobin level (g/dL) over this same time period. Panel c corresponds to changes in the patient’s platelet level (K/mcL) over this same periodBack to article page